What happened with MYGN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Myriad Genetics analyzes patients’ genes and gene expression to help healthcare providers understand disease risk, cancer progression and likely responses to medicines. Cancer testing supplies most of its revenue, with hereditary cancer testing the largest category. MyRisk assesses inherited cancer risk, while other cancer tests help guide treatment. The company also offers prenatal screening, including Prequel, and GeneSight, which uses a patient’s genetic makeup to inform mental-health medication decisions.
Private insurers and other private healthcare payors supply most revenue; government healthcare programs and patients also pay for tests. Payment depends on coverage rules and reimbursement rates, not simply on completing a test. UnitedHealthcare ended coverage for GeneSight under certain plans, reducing the revenue Myriad receives from that business. Most tests are used only once per patient, so continued sales depend on reaching new patients or developing new tests.
Myriad must maintain laboratory certifications and applicable licenses to perform testing and qualify for reimbursement. Tests used to determine whether particular cancer treatments are suitable also require FDA clearance or approval before U.S. marketing, limiting which uses the company can sell.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Myriad Genetics Inc also depends on insurer coverage and reimbursement: UnitedHealthcare's withdrawal of GeneSight coverage reduced mental-health revenue despite higher testing volume.
Natera competes with Myriad Genetics Inc for prenatal, carrier-screening, hereditary-cancer and cancer-monitoring tests, selling directly and through laboratory and distribution partners. Its prenatal and cancer-monitoring business is the part to watch against Myriad's women's-health tests and Precise MRD.
Tempus AI competes with Myriad Genetics Inc in hereditary-cancer and tumor testing, and in tests that help guide neuropsychiatric drug choices. Watch its diagnostic testing for healthcare providers, especially those drug-choice tests that compete with GeneSight, rather than its separate data-licensing business.
BillionToOne, Inc.'s UNITY tests compete with Myriad Genetics Inc's Prequel and Foresight for prenatal and carrier-screening orders, using maternal blood to assess fetal risk. Its U.S. prenatal sales team grew from 120 representatives at December 31, 2024 to 177 at December 31, 2025—a concrete measure of its expanding sales effort in this market.
Veracyte, Inc.'s Decipher Prostate competes with Myriad Genetics Inc's Prolaris in genetic tests that guide prostate-cancer treatment. Veracyte earns most of its revenue from Decipher Prostate and Afirma, but its push to expand Decipher Prostate use is the part most relevant to Prolaris.
Labcorp competes with Myriad Genetics Inc across prenatal and carrier screening, oncology and mental-health testing, collecting testing revenue from clients, patients, government programs and third-party payers. Its broad laboratory network and test menu put its diagnostic-testing business, rather than its drug-development services, in direct competition with Myriad.
Quest Diagnostics competes with Myriad Genetics Inc for oncology, women's-health and mental-health testing orders, providing laboratory results to clinicians and hospitals. Its network serves approximately 612,000 clinician and hospital accounts, making its reach into those customers relevant to Myriad's competition for orders.
Guardant Health competes with Myriad Genetics Inc in tests that guide cancer treatment and detect cancer remaining after treatment through blood samples. Watch its Guardant360 and Guardant Reveal testing for clinical customers, for which it submits qualifying U.S. claims to Medicare and private payers, rather than its separate Shield screening business.
Caris Life Sciences, Inc. competes with Myriad Genetics Inc by selling tumor-profiling tests that help oncologists choose cancer therapies. Its tissue-based MI Profile and blood-based Caris Assure are the offerings to watch alongside Myriad's Precise Tumor.
NeoGenomics, Inc. competes with Myriad Genetics Inc for oncologists' cancer molecular-profiling and blood-based testing business, including community practices. It sells laboratory testing and expert interpretation to those practices, the same customer setting Myriad sees as supporting its Precise MRD business.
Fulgent Genetics, Inc. competes with Myriad Genetics Inc for prenatal and carrier-screening orders from women's-health providers, earning laboratory-services revenue from testing and physician interpretation. Its screening offerings are the relevant overlap with Myriad's Prequel and Foresight, not its separate therapeutic-development business.
MDxHealth SA's GPS mdx directly competes with Myriad Genetics Inc's Prolaris, selling tissue-based genetic testing that helps men with prostate cancer choose treatment or active surveillance. GPS mdx is the test to watch, rather than MDxHealth's tests used earlier in risk assessment and diagnosis.
Personalis, Inc. competes with Myriad Genetics Inc in genomic tests that find residual or recurrent cancer and help physicians select treatment. Its physician-facing cancer-monitoring services are the overlap to watch against Myriad's Precise MRD, distinct from its research and sequencing services sold to drug and diagnostic companies.
Myriad Genetics Inc depends on Illumina's non-exclusive technology license for Prequel prenatal screening and pays Illumina royalties based on Prequel testing volume. That makes the license terms and Myriad's ability to retain the license more relevant than Illumina's overall sales of sequencing equipment and supplies.
Fed Interest Rate Decision
The Fed’s rate decision shapes borrowing costs across the economy and can change the interest Myriad pays on its SOFR-linked Credit Facility, affecting the cash available for its genetic testing business.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s rate is higher than expected, rates across the economy may rise; if that lifts SOFR above the facility’s 2.5% floor, Myriad’s interest expense may increase, leaving less cash for testing operations and development.
If it comes in below expectations
If the Fed’s rate is lower than expected, rates across the economy may fall; if that brings SOFR down while it remains above the 2.5% floor, Myriad’s interest expense may decrease, leaving more cash for testing operations and development.
Tempus AI, Inc. earningsTEM
Tempus AI's report can show how demand for tests that guide psychiatric drug choices is changing, and whether GeneSight faces more competition for clinicians' orders.
Focus on Tempus's drug-choice testing for healthcare providers, not its data-licensing business. If use or revenue for those tests grows, clinicians are adopting more of a competing product and GeneSight may face more pressure for orders. If that business weakens, competitive pressure may ease, but this does not establish GeneSight's own test volume or reimbursement.
Myriad Genetics Inc earningsThis company
Myriad Genetics earns revenue from genetic tests, and this report will show whether demand across its tests is holding up against reimbursement pressure, especially how much GeneSight earns per test.
Read test volumes alongside average revenue per test, especially for GeneSight. Rising volumes with revenue per test holding steady would show that demand is still converting into revenue; rising volumes but falling revenue per test would show reimbursement pressure offsetting more of that demand and limiting Myriad's revenue growth.
BillionToOne, Inc. earningsBLLN
BillionToOne's report can show how demand for prenatal screening is changing in a market where its tests compete with Myriad's Prequel and Foresight for customers.
Watch revenue or test volume in BillionToOne's prenatal business. Growth would show greater use of its screening option by women's-health providers and patients, potentially intensifying competition for Myriad's Prequel and Foresight. Weakness would suggest less competitive pressure, but a rival's results are not a measure of Myriad's own orders.
Caris Life Sciences, Inc. earningsCAI
Caris Life Sciences' report can show whether demand for its tumor-profiling tests is changing; oncologists use those tests to choose treatments, putting them in competition with Myriad's Precise Tumor.
Focus on Caris's clinical tumor-testing business rather than treating its overall results as a measure of testing demand. Growth would show more oncologists using Caris's tumor-profiling services and could mean stronger competition for Precise Tumor. Weakness would point to less pressure from Caris, but would not establish Myriad's orders.
Veracyte, Inc. earningsVCYT
Veracyte's report can show how use of Decipher Prostate is changing; it competes with Myriad's Prolaris in tests that help guide prostate-cancer treatment.
Look for results specific to Veracyte's Decipher Prostate business, not company-wide revenue that may be driven by other tests such as Afirma. Growth in Decipher use or related revenue would show greater physician adoption of a test that competes with Prolaris and could raise pressure on Prolaris for orders. Weakness could ease that pressure, but would not prove Prolaris is growing.
Natera, Inc. earningsNTRA
Natera's report can show how demand for clinical cancer-monitoring tests is changing; those tests compete with Myriad's Precise MRD for physicians' orders.
Focus on Natera's clinical cancer-monitoring business, not its prenatal or other testing. If use or revenue for these tests grows, physicians are adopting more of a competing cancer-monitoring approach and Precise MRD may face more competition for orders. If it weakens, pressure from Natera may ease, but this does not establish Myriad's own test volume.
